AlzeCure Gets Green Light for 3rd Phase 1 Study of ACD856

AlzeCure Gets Green Light for 3rd Phase 1 Study of ACD856

305761

AlzeCure Gets Green Light for 3rd Phase 1 Study of ACD856

AlzeCure Pharma has been granted approval by Swedish regulatory authorities to start its third Phase 1 study of ACD856, the company’s leading therapeutic candidate for Alzheimer’s disease. The study is designed to test multiple ascending doses of the medication, which means that the amount of ACD856 will be increased for each new group of participants. The primary goal is to evaluate the tolerability and safety of ACD856 after repetitive dosing, as well as to determine…

You must be logged in to read/download the full post.